Navigation Links
Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
Date:9/14/2010

BALTIMORE, Sept. 14 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN). ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration. Arcion recently announced positive top-line results from a Phase 2b double-blind, randomized, placebo-controlled clinical trial of ARC-4558 in adult patients with PDN. The Company also recently held an End of Phase 2 meeting with the FDA and the ARC-4558 program is now poised to enter Phase 3 studies.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs typically qualify for priority review, thereby expediting the FDA review process.

"This Fast Track designation is an important recognition by the FDA of the potential for ARC-4558 to address the unmet need for better agents to control the pain involved in PDN, a serious condition," said James Campbell, M.D., Chief Executive Officer of Arcion. "Having the Fast Track designation will be of great value to Arcion as we work with the FDA to come to an agreement on the final Phase 3 program, as well as open the way to a potential priority review."  

About ARC-4558

ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride (HCL) for topical administration to the painful area in order to manage the neuropathic pain associated with painful diabetic neuropathy (PDN).  Topical clonidine, thr
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
2. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
3. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
4. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
5. Halozyme Therapeutics Announces Public Offering of Common Stock
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
10. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Radiology information ... is used to store, manipulate, and distribute patient ... patient tracking and scheduling system, result reporting, and ... with HIS and other databases improves the hospital ... patient scheduling, patient list management, radiology department workflow ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... LEUVEN, Belgium, September 29 , - Results ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused ... and cancer,announces positive results from its MITI IV ... efficacy of microplasmin when administered,intravenously to acute stroke ...
... Dikembe Mutombo Foundation to improve healthcare,system in the ... Sept. 25 The Clinton Global,Initiative recognized BD ... a,leading global medical technology company, for its commitment ... system monitoring and,healthcare worker safety at the Biamba ...
Cached Medicine Technology:ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 2ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 3ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 4Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
(Date:12/19/2014)... December 19, 2014 If you have ... difficulty breathing, you probably wished you had an arsenal ... COPD, cystic fibrosis, and other breathing disorders. Currently, the ... and avoiding triggers, but other common treatments do exist. ... conference in San Antonio, TX, 34 asthma educators responded ...
(Date:12/19/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Gliquidone manufacturers and is a valuable source of ... the industry. , Firstly, the report provides a basic ... manufacturing technology. Then, the report explores the international and ...
(Date:12/19/2014)... A new study suggests a possible link between certain ... night sweats -- and higher rates of hip fractures ... menopause, affecting about 60 percent of women. The hormonal ... they then face a higher risk of weakened bones ... moderate or severe menopausal symptoms are more likely to ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
Breaking Medicine News(10 mins):Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... Ind., Jan. 20 Conseco, Inc. (NYSE: ... a stockholder rights plan,designed to protect stockholder value by ... tax net operating loss carryforwards under,Section 382 of the ... value,of those tax assets upon an "ownership change." ...
... purchased raw milk from the Conestoga Valley Dairy Farm ... to the risk of Salmonella contamination, Agriculture Secretary Dennis ... to kill disease-causing bacteria or homogenized. Pennsylvania farms selling ... samples tested in a laboratory due to the health ...
... Foundation to Host Five Cancer Fighters on January 30th ... Jan. 20 Lillians(TM), The Hippest Shoppe in Town(R) ... announced that it will postpone "the dance," its annual ... until Friday, Oct. 23, 2009, at the Medina Entertainment ...
... enterprise WLAN solution for point-of-care, voice and AeroScout asset ... Inc. (NYSE: MOT ) today announced ... LAN (WLAN) solution to support several of its current ... a 680-bed facility providing quality patient care in Montreal, ...
... other chemicals boost their odds of respiratory trouble, ... -- Frequent exposure to hospital cleaning products and ... to a U.S. study that included 3,650 Texan ... researchers found that nurses regularly exposed to cleaning ...
... MassMutual,s Retirement Services Division has added three new ... third-party administrators (TPA). The new TPA relationship managers ... investment change processing, product and service education and ... platform. Karen Buoniconti joined MassMutual,s TPA ...
Cached Medicine News:Health News:Conseco Adopts Stockholder Rights Plan 2Health News:Conseco Adopts Stockholder Rights Plan 3Health News:Conseco Adopts Stockholder Rights Plan 4Health News:Conseco Adopts Stockholder Rights Plan 5Health News:Lillians(TM) Postpones 'The Dance' Fundraising Event; New Date Is October 23, 2009 2Health News:Montreal Jewish General Hospital Improves Care and Reduces Costs With Motorola's Enterprise Mobility Solution 2Health News:Montreal Jewish General Hospital Improves Care and Reduces Costs With Motorola's Enterprise Mobility Solution 3Health News:Cleaning Products Up Nurses' Asthma Risk 2Health News:MassMutual Retirement Services Appoints Three New TPA Relationship Managers 2
... (generic name: ferumoxsil) is Advanced Magnetics' oral ... loops of the bowel from other abdominal ... and tissues in the abdomen without contrast ... tissues cannot be easily distinguished from the ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
... well-established, second-generation ultrasound medical diagnostic product with ... borders of the heart. This allows doctors ... the heart during an ultrasound scanning procedure, ... heart condition and providing guidance for the ...
... is designed for accuracy and for modularity, ... or "elbow" aimers and also between using ... tibial tunnel. The system is easy to ... reproducibility and accuracy gained from rigidity of ...
Medicine Products: